23:30 04/05/2016 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Check on Earnings
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Check on Earnings
Franklin Independent - 8 hours ago
Wall Street will be paying particular attention when Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issues their next quarterly report which is anticipated to go out on or about 2016-05-09 for the period ending on 2016-03-31.
Arena (ARNA) Q1 Earnings: What's in Store for the Stock? - Yahoo News
Arena Pharmaceuticals Incorporated (NASDAQ:ARNA) Short Interest Decreased By ... - The Post

16:45 04/05/2016 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) ABR Of 2.5
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) ABR Of 2.5
Enterprise Leader - 14 hours ago
Analysts have a buy call on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock. As of 2016-05-03, it had an ABR of 2.5.

13:11 04/05/2016 Two Biotech Stocks Are Just So Hot Right Now: Arena Pharmaceuticals, Inc ...
Two Biotech Stocks Are Just So Hot Right Now: Arena Pharmaceuticals, Inc ...
Zergwatch - 18 hours ago
Arena Pharmaceuticals, Inc. (ARNA) ended last trading session with a change of -5.26 percent. It trades at an average volume of 2.01M shares versus 1.37M shares recorded at the end of last trading session.

11:41 04/05/2016 Traders Checklist Stocks: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Traders Checklist Stocks: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Street Updates - 19 hours ago
Arena Pharmaceuticals, Inc. (ARNA) recently stated that it will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m.

22:36 03/05/2016 Arena Pharmaceuticals Inc. (ARNA) Drops 5.26% on May 03
Arena Pharmaceuticals Inc. (ARNA) Drops 5.26% on May 03
Equities.com - May 3, 2016
Arena Pharmaceuticals Inc. (ARNA) was one of the Russell 2000's biggest losers for Tuesday May 03 as the stock slid 5.26% to $1.62, a loss of $-0.09 per share.

19:33 03/05/2016 Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) earnings reaction history
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) earnings reaction history
Zergwatch - May 3, 2016
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is expected to announce first quarter financial results estimated on 05/09/2016.
Trending Stock Analyst Review: Arena Pharmaceuticals, Inc. (ARNA) - CWRU Observer
Arena Pharmaceuticals, Inc. (ARNA) Upgraded by Zacks Investment Research to Hold - Web Breaking News

13:56 03/05/2016 Biotech Movers: St. Jude Medical, Inc. (NYSE:STJ) , Arena Pharmaceuticals, Inc ...
Biotech Movers: St. Jude Medical, Inc. (NYSE:STJ) , Arena Pharmaceuticals, Inc ...
Is stories - May 3, 2016
St. Jude Medical, Inc. (NYSE:STJ) increased +0.13% to $76.30 while traded 11.04 million shares on 5/2/2016. The stock price negotiated for value between $75.99 to $76.70 in recent trading session.

13:00 02/05/2016 Biotech Companies To Look Out For: Illumina Inc. (ILMN), Arena Pharmaceuticals ...
Biotech Companies To Look Out For: Illumina Inc. (ILMN), Arena Pharmaceuticals ...
Zergwatch - May 2, 2016
Illumina Inc. (ILMN) ended last trading session with a change of -0.56 percent. It trades at an average volume of 1.54M shares versus 2.15M shares recorded at the end of last trading session.

14:07 13/04/2016 Active Biotech Stock News: Arena Pharmaceuticals, Inc. (ARNA), BioMarin ...
Active Biotech Stock News: Arena Pharmaceuticals, Inc. (ARNA), BioMarin ...
Zergwatch - Apr 13, 2016
Arena Pharmaceuticals, Inc. (ARNA) ended last trading session with a change of 2.72 percent. It trades at an average volume of 2.15M shares versus 3.25M shares recorded at the end of last trading session.
Stocks Dip in Most Active Notes: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ... - Seneca Globe
Analyst Review Alert: Arena Pharmaceuticals (NASDAQ:ARNA) - CWRU Observer

22:22 08/04/2016 Arena Pharmaceuticals, Inc. Rides Celgene's Coattails to Big Gains in March
Arena Pharmaceuticals, Inc. Rides Celgene's Coattails to Big Gains in March
Motley Fool - Apr 8, 2016
What: Shares of Arena Pharmaceuticals (NASDAQ:ARNA), a biopharmaceutical company focused on the development of therapies to treat a variety of unmet diseases, surged 32% in the month of March based on data from S&P Global Market Intelligence.